Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2020

View Archived Issues

Greenwich LifeSciences presents phase IIb data for cancer vaccine GP-2/GM-CSF

Oncolytic virus combines best of both immune worlds

Rule-based screening for degraders

Activity profiling and crystal structures to guide the design of SARS-CoV-2 PLpro inhibitors

RGFP-963 demonstrates promise in mouse models of ALS

Phase I and II clinical data reported for human IL-12 gene therapy Ad-RTS-hIL-12

HDAC6 inhibition as potential new therapeutic strategy for ALS

Prothena reports positive 9-month data from phase I study of PRX-004

Positive topline data presented from phase Ib study of EDP-1815 in atopic dermatitis

Bristol-Myers Squibb discovers Nuclear receptor ROR-gammaT agonists

New aryl hydrocarbon receptor antagonists disclosed by Antidote IP Holdings

Dana-Farber Cancer Institute patents focal adhesion kinase inhibitors

New Na(+)/H(+) exchanger 3 inhibitors identified at Lilly

DMC issues recommendation regarding global phase III study of PLX-PAD in CLI

Senju Pharmaceutical describes PAC1/VPAC1/VPAC2 receptor ligands

New preclinical data confirms efficacy of apelin agonists in ARDS

Dosing initiates in phase I study of ALT-801 for the treatment of NASH

Resolve presents positive phase IIa data for RSLV-132 in patients with SLE

Activity seen with ZEN-003694 plus talazoparib in metastatic triple-negative breast cancer

Phase III VIOLET studies of oteseconazole for recurrent VVC meet primary endpoint

SABCS2020: Verzenio continues to show benefit, but time may topple monarchE

First phase III induction study with upadacitinib in ulcerative colitis meets primary endpoint

Applied Therapeutics reports MRS data on reduction of galactitol levels with AT-007 for galactosemia

ObsEva reports further phase III data on use of linzagolix for bleeding due to uterine fibroids

Editas submits IND for EDIT-301 for sickle cell disease

Cytokinetics advances phase II trial of CK-3773274 for symptomatic obstructive HCM

Rocket reports preliminary phase I data on RP-A501 for Danon disease

Week 48 data reported from phase III PEGASUS trial of pegcetacoplan in PNH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...